We are pleased to announce that, with the recent progress in the development of its unique platform technology, MaxiVAX is morphing into a new company with a reinforced team, repurposed asset, and a new name: Release Tx which delivers differentiated technology for protein delivery behind the BBB, as well as, enabling the treatment of Genetic diseases without Gene Therapy.
This exciting transition marks a strategic evolution in the company’s mission and focus.
Release Tx is dedicated to advancing breakthrough therapies targeting a wide range of diseases and conditions.
Stay tuned for further updates!
Release Tx Team.